FENCLOFENAC

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C14H10Cl2O3
Molecular Weight	297.133
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)CC1=CC=CC=C1OC2=CC=C(Cl)C=C2Cl

InChI

InChIKey=IDKAXRLETRCXKS-UHFFFAOYSA-N

InChI=1S/C14H10Cl2O3/c15-10-5-6-13(11(16)8-10)19-12-4-2-1-3-9(12)7-14(17)18/h1-6,8H,7H2,(H,17,18)

HIDE SMILES / InChI

Molecular Formula	C14H10Cl2O3
Molecular Weight	297.133
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.ndrugs.com/?s=flenac
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/2937024 https://www.ncbi.nlm.nih.gov/pubmed/970297

Fenclofenac (Flenac) is a non-steroidal anti-inflammatory drug previously used in rheumatism. Fenclofenac was shown to possess anti-inflammatory, antinociceptive and antipyretic properties. Flenac is an acetic acid nonsteroidal antiinflammatory drug (NSAID) with analgesic and antipyretic properties. Flenac is used to treat pain, dysmenorrhea, ocular inflammation, osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and actinic keratosis. It has mild immunosuppressive effects and may displace thyroid hormone from its binding protein. The antiinflammatory effects of Flenac are believed to be due to inhibition of both leukocyte migration and the enzyme cylooxygenase (COX-1 and COX-2), leading to the peripheral inhibition of prostaglandin synthesis. As prostaglandins sensitize pain receptors, inhibition of their synthesis is responsible for the analgesic effects of Flenac. Antipyretic effects may be due to action on the hypothalamus, resulting in peripheral dilation, increased cutaneous blood flow, and subsequent heat dissipation. Fenclofenac, despite passing animal toxicity tests in 10 animal species (mice, rats, guinea pigs, ferrets, rabbits, cats, dogs, pigs, horses, and monkeys), produced severe liver toxicity in humans. Due to its side effects it was withdrawn from the UK in 1984.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Triiodothyronine metabolism 1 Target ID: Triiodothyronine metabolism Sources: https://www.ncbi.nlm.nih.gov/pubmed/2912709	Inhibitor 8504		69.0 µM [IC50]
Cyclooxygenase 89 Target ID: CHEMBL2094253 Sources: http://www.ndrugs.com/?s=flenac&t=actions	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Ankylosing spondylitis 33 Sources: http://www.ndrugs.com/?s=flenac	Palliative	Approved 8583	Flenac Approved Use Acute and long-term use in the relief of signs and symptoms of ankylosing spondylitis (delayed-release tablets); acute treatment of migraine attacks with or without aura in adults (oral solution); relief of mild to moderate pain (immediate-release capsules and tablets); relief of signs and symptoms of osteoarthritis and rheumatoid arthritis (immediate-release, ER, and delayed-release tablets); treatment of primary dysmenorrhea (immediate-release tablets).
Osteoarthritis 157 Sources: http://www.ndrugs.com/?s=flenac	Palliative	Approved 8583	Flenac Approved Use Acute and long-term use in the relief of signs and symptoms of ankylosing spondylitis (delayed-release tablets); acute treatment of migraine attacks with or without aura in adults (oral solution); relief of mild to moderate pain (immediate-release capsules and tablets); relief of signs and symptoms of osteoarthritis and rheumatoid arthritis (immediate-release, ER, and delayed-release tablets); treatment of primary dysmenorrhea (immediate-release tablets).
Rheumatoid arthritis 320 Sources: http://www.ndrugs.com/?s=flenac	Palliative	Approved 8583	Flenac Approved Use Acute and long-term use in the relief of signs and symptoms of ankylosing spondylitis (delayed-release tablets); acute treatment of migraine attacks with or without aura in adults (oral solution); relief of mild to moderate pain (immediate-release capsules and tablets); relief of signs and symptoms of osteoarthritis and rheumatoid arthritis (immediate-release, ER, and delayed-release tablets); treatment of primary dysmenorrhea (immediate-release tablets).

C_max

Value	Dose	Analyte	Population
18.2 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7250145/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	FENCLOFENAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
45.3 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7250145/	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:	FENCLOFENAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
63.5 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7250145/	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:	FENCLOFENAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
86.9 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7250145/	600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	FENCLOFENAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

AUC

Value	Dose	Analyte	Population
457 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7250145/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	FENCLOFENAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1323 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7250145/	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:	FENCLOFENAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1716 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7250145/	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:	FENCLOFENAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
884 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7250145/	600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	FENCLOFENAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

T_1/2

Value	Dose	Analyte	Population
24.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7250145/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	FENCLOFENAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
32.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7250145/	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:	FENCLOFENAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
27.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7250145/	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:	FENCLOFENAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
25.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7250145/	600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	FENCLOFENAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

F_unbound

Value	Dose	Co-administered	Analyte	Population
0.5% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6628527/			FENCLOFENAC plasma	Homo sapiens

Doses

Dose	Population	Adverse events
1200 mg 3 times / day multiple, oral Highest recorded dose Dose: 1200 mg, 3 times / day Route: oral Route: multiple Dose: 1200 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/486951/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/486951/	Disc. AE: Edema legs, Proteinuria... AEs leading to discontinuation/dose reduction: Edema legs (grade 3) Proteinuria Sources: https://pubmed.ncbi.nlm.nih.gov/486951/
1800 mg 3 times / day multiple, oral Highest studied dose Dose: 1800 mg, 3 times / day Route: oral Route: multiple Dose: 1800 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3518772/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/3518772/	Other AEs: Indigestion, Vomiting... Other AEs: Indigestion (16.7%) Vomiting (6.7%) Drowsiness (33.3%) Haematuria (38.9%) Skin irritation (grade 1, 5.5%) Skin blotches (11.1%) Alkaline phosphatase Sources: https://pubmed.ncbi.nlm.nih.gov/3518772/

AEs

AE	Significance	Dose	Population
Proteinuria	Disc. AE	1200 mg 3 times / day multiple, oral Highest recorded dose Dose: 1200 mg, 3 times / day Route: oral Route: multiple Dose: 1200 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/486951/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/486951/
Edema legs	grade 3 Disc. AE	1200 mg 3 times / day multiple, oral Highest recorded dose Dose: 1200 mg, 3 times / day Route: oral Route: multiple Dose: 1200 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/486951/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/486951/
Alkaline phosphatase		1800 mg 3 times / day multiple, oral Highest studied dose Dose: 1800 mg, 3 times / day Route: oral Route: multiple Dose: 1800 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3518772/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/3518772/
Skin blotches	11.1%	1800 mg 3 times / day multiple, oral Highest studied dose Dose: 1800 mg, 3 times / day Route: oral Route: multiple Dose: 1800 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3518772/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/3518772/
Indigestion	16.7%	1800 mg 3 times / day multiple, oral Highest studied dose Dose: 1800 mg, 3 times / day Route: oral Route: multiple Dose: 1800 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3518772/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/3518772/
Drowsiness	33.3%	1800 mg 3 times / day multiple, oral Highest studied dose Dose: 1800 mg, 3 times / day Route: oral Route: multiple Dose: 1800 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3518772/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/3518772/
Haematuria	38.9%	1800 mg 3 times / day multiple, oral Highest studied dose Dose: 1800 mg, 3 times / day Route: oral Route: multiple Dose: 1800 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3518772/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/3518772/
Vomiting	6.7%	1800 mg 3 times / day multiple, oral Highest studied dose Dose: 1800 mg, 3 times / day Route: oral Route: multiple Dose: 1800 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3518772/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/3518772/
Skin irritation	grade 1, 5.5%	1800 mg 3 times / day multiple, oral Highest studied dose Dose: 1800 mg, 3 times / day Route: oral Route: multiple Dose: 1800 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3518772/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/3518772/

PubMed

Title	Date	PubMed
Penicillamine induced myasthenia reactivated by gold.	1984-01-21	6419855

Patents

Sample Use Guides

In Vivo Use Guide

Usual Adult Dose for Osteoarthritis Flenac free acid capsules: 35 mg orally 3 times a day Flenac potassium immediate-release tablets: 50 mg orally 2 or 3 times a day Flenac sodium enteric-coated tablets: 50 mg orally 2 or 3 times a day or 75 mg orally 2 times a day Maximum dose: 150 mg daily Flenac sodium extended-release tablets: 100 mg orally once a day

Route of Administration: Oral

In Vitro Use Guide

Fenclofenac inhibited cellular uptake of T3 in rat H4 hepatoma cells with IC50 69 uM.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:01:56 GMT 2025` Edited by `admin` on `Mon Mar 31 18:01:56 GMT 2025`
Record UNII	Y01JW64D01
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

R 67408

Preferred Name

English

FENCLOFENAC

Official Name

English

Fenclofenac [WHO-DD]

Common Name

English

RX-67408

Code

English

BENZENEACETIC ACID, 2-(2,4-DICHLOROPHENOXY)-

Common Name

English

FENCLOFENAC [MART.]

Common Name

English

RX 67408

Code

English

R-67408

Code

English

(O-(2,4-DICHLOROPHENOXY)PHENYL)ACETIC ACID

Common Name

English

fenclofenac [INN]

Common Name

English

FENCLOFENAC [USAN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1323